EndoTODAY | EndoATLAS | OPD

Parasite | Eso | Sto | Cancer | ESD

Boxim | DEX | Sono | Schedule

Home | Recent | Blog | Links

EndoTODAY ³»½Ã°æ ±³½Ç


[ÀÚ°¡¸é¿ªÀ§¿°. Autoimmune gastritis] - ðû

- Åä·Ð, ¸Þ¸ð 2024-1-18. ±èż¼ ¼±»ý´Ô

1. Á¤ÀÇ, º´¸® »ý¸®¿Í º´¸® ¼Ò°ß

2. Áø´Ü°ú ³»½Ã°æ ¼Ò°ß

3. ¿ì¸®³ª¶óÀÇ Ã¹ ÀÚ°¡¸é¿ªÀ§¿° case series (2021, °Ç±¹´ë À̼±¿µ ±³¼ö´Ô)

4. ÀÓ»ó»ó

5. ÀÚ°¡¸é¿ªÀ§¿°°ú ½Å°æ³»ºÐºñ Á¾¾ç

6. ÀÚ°¡¸é¿ªÀ§¿°°ú À§¾Ï

7. ÀÚ°¡¸é¿ªÀ§¿°°ú µ¿¹ÝµÇ´Â Áúȯ - °©»ó¼±Áúȯ µî

8. FAQs

9. References

- Áú¹®°ú ´äº¯ 2022-10-12. ¾È¿ëȯ ¿øÀå´Ô

My favorite gastric lesions by Elizabeth Anne Montgomery ÀÚ°¡¸é¿ª¼º À§¿° ¹× °ü·Ã Áúȯ (carcinoid, pyloric gland adenoma µî)¿¡ ´ëÇÑ ÇÑ º´¸®ÇÐÀÚÀÇ »ó¼¼ÇÑ ¼³¸í


1. Á¤ÀÇ, º´Å »ý¸®¿Í º´¸® ¼Ò°ß

Definition: a chronic progressive inflammatory condition that results in the replacement of the parietal cell mass by atrophic and metaplastic mucosa

Forestomach°ú hind stomachÀÇ ¹ß»ýÇÐÀû °úÁ¤ÀÌ ´Ù¸¨´Ï´Ù (Rugge. Dig Liver Dis 2021)

ÀÚ°¡¸é¿ª¼º À§¿°ÀÇ º´Å»ý¸®´Â genetic factor¿Í enviornmental factor°¡ ¸ðµÎ ¾ð±ÞµÇ°í ÀÖ½À´Ï´Ù. HLA-DR°ú HLA-DQ¿Í °ü·ÃÀÌ ÀÖ´Ù´Â ÁÖÀåÀÌ ÀÖ½À´Ï´Ù. Environmental factors, including infections (e.g. Helicobacter pylori) and exposure to certain dietary components, may trigger the autoimmune response in genetically susceptible individuals. In particular, molecular mimicry, where microbial or dietary antigens resemble self-antigens, may activate autoreactive immune cells targeting the gastric mucosa (Cureus 2023).

Greenson Diagnostic Pthology Gastrointestinal (2nd ed)

ÀÚ°¡¸é¿ª¼º À§¿° ¹× °ü·Ã Áúȯ (carcinoid, pyloric gland adenoma µî)¿¡ ´ëÇÑ ÇÑ º´¸®ÇÐÀÚÀÇ »ó¼¼ÇÑ ¼³¸í YouTube µ¿¿µ»óÀ» ¼Ò°³ÇÕ´Ï´Ù.

ÇÑ Áõ·ÊÀÇ º´¸® ¼Ò°ßÀÔ´Ï´Ù.

Antral mucosa

Body mucosa. Parietal cell¿Í chief cell·Î ÀÌ·ç¾îÁø oxyntic gland°¡ »ç¶óÁ³°í ±× ÀÚ¸®¿¡¼­ intestinal/pseudopyloric gland°¡ °üÂûµÈ´Ù

¾Õ »çÁø °í¹èÀ²


2. ÀÚ°¡¸é¿ªÀ§¿°ÀÇ Áø´Ü°ú ³»½Ã°æ ¼Ò°ß

±¹³»¿¡¼­ ÀÚ°¡¸é¿ªÀ§¿°ÀÇ Áø´Ü±âÁØÀº È®¸³µÇ¾î ÀÖÁö ¾Ê½À´Ï´Ù. ÀϺ»ÀÇ Áø´Ü±âÁØÀº ¾Æ·¡°ú °°½À´Ï´Ù. (Digestive endoscopy 2022)

Reverse atrophy

False-negative serological tests: Seological tests for autoantibodies, such as APCA and AIFA, are valuable diagnostic markers for autoimmune gastritis. However, false-negative results can occure, particularly in the early stages of the disease or in patients with atypical serological proviles. Relying solely on serological tests may lead to missed diagnoses, highlighting the importance of a comprehensive diagnostic approach that includes clinical evaluation, endoscopy, histology, and consideration of other relevant factors (Cureus 2023).

³»½Ã°æ °Ë»çÀÇ sensitivity°¡ 30%´ë¶ó´Â ÁÖÀåµµ ÀÖ½À´Ï´Ù. Ãʱ⿡´Â Áø´ÜÇϱ⠾î·Æ±â ¶§¹®ÀÔ´Ï´Ù.

Reverse atrophy°¡ ¶Ñ·ÇÇÑ ÀÚ°¡¸é¿ª¼º À§¿°ÀÇ Áø´Ü¿¡¼­ ³»½Ã°æÀÇ ¿ªÇÒÀº ¸Å¿ì Áß¿äÇÕ´Ï´Ù. Ãʱâ ÀÚ°¡¸é¿ª¼º À§¿°¿¡¼­´Â Áõ»óÀ̳ª Ç÷ûÇÐÀû º¯È­¿¡ ºñÇÏ¿© Á¡¸·º¯È­°¡ °æ¹ÌÇϹǷΠ³»½Ã°æ ¼Ò°ßÀÌ ¶Ñ·ÇÇÏÁö ¾Ê½À´Ï´Ù. ÀÌ °æ¿ì¿¡´Â ³»½Ã°æÀ̳ª ½ÉÁö¾î´Â pepsinogen º¯È­º¸´Ù gastrin »ó½ÂÀ̳ª Ç×üº¯È­·Î Áø´ÜÇÒ ¼ö ÀÖ½À´Ï´Ù.

Reverse atrophy

Reverse atrophy

Reverse atrophy

ÀÚ°¡¸é¿ªÀ§¿°À» Áø´ÜÇÑ ÈÄ À۳⠻çÁøÀ» ¿­¾îº¸¾Ò´õ´Ï reverse atrophy°¡ ¸Å¿ì ÇöÀúÇß½À´Ï´Ù. À۳⿡ ÀǽÉÇÏ¿´´õ¶ó¸é ¾î¶®À»±î ½Í½À´Ï´Ù. ¾ÆÁÖ ÃÖ±Ù¿¡ ¾Ë·ÁÁö±â ½ÃÀÛÇÏ¿´½À´Ï´Ù¸¸, ¿ì¸®³ª¶ó¿¡¼­µµ ÀÚ°¡¸é¿ªÀ§¿°ÀÌ ÀÖ½À´Ï´Ù. »ý°¢º¸´Ù ¸¹½À´Ï´Ù.

White globe appearance: ÀÚ°¡¸é¿ª¼º À§¿°¿¡¼­µµ º¸ÀÏ ¼ö ÀÖÁö¸¸ PPI ¿À·¡ »ç¿ëÇÑ °æ¿ì¿¡¼­µµ °üÂûµÉ ¼ö ÀÖ½À´Ï´Ù.

ÀÚ°¡¸é¿ªÀ§¿° ȯÀÚ¿¡¼­ neuroendocrine hyperplasia, neuroendocrine neoplasia (»óÇÇÇÏÁ¾¾çÀ¸·Î °üÂûµÇ±âµµ ÇÕ´Ï´Ù)°¡ È£¹ßÇÏ´Â °ÍÀº Àß ¾Ë·ÁÁ® ÀÖ½À´Ï´Ù. ±×·¯³ª ÀÚ°¡¸é¿ª¼º À§¿° ȯÀÚ¿¡¼­ hyperplastic polypµµ È£¹ßÇÕ´Ï´Ù. ÀÚ°¡¸é¿ª¼º À§¿°¿¡¼­ ¹ß»ýÇÑ hyperplastic polyp¿¡¼­´Â dysplastic change, cancerous transformationÀÌ ÈçÇÏ´Ù´Â ÁÖÀåµµ ÀÖ½À´Ï´Ù.

2022-10-12 ¾È¿ëȯ ¿øÀå´Ô °­ÀÇ

2022-10-12 ¾È¿ëȯ ¿øÀå´Ô °­ÀÇ


[2023-10-27] ÀÚ°¡¸é¿ªÀ§¿° ¿¬±¸ÀÚÀ̽Š¾È¿ëȯ ¿øÀå´Ô²²¼­ ÃÖ±Ù ¿¬±¸ °á°ú¸¦ KDDW2023¿¡ ¹ßÇ¥ÇϽŴٴ ¿¬¶ôÀ» º¸³»¿À¼Ì½À´Ï´Ù.

PDF

"À̹ø¿¡ KDDW 2023¿¡ Æ÷½ºÅ͸¦ Çϳª ¹ßÇ¥ÇÏ°Ô µÇ¾î ÀÌ·¸°Ô ¿¬¶ô µå¸®°Ô µÇ¾ú½À´Ï´Ù. ÁÖÁ¦´Â autoimmune gastritis ȯÀÚÀÇ endoscopic atrophy º¯È­¿¡ ´ëÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦ ȯÀÚµé Áß¿¡¼­ 3ȸ ÀÌ»ó, Àû¾îµµ 6³â ÀÌ»ó, °ú°Å ½ÃÇàÇÑ ³»½Ã°æ »çÁøÀÌ Àִ ȯÀÚµéÀ» ¸ð¾Æ¼­ endoscopic atrophyÀÇ º¯È­¸¦ º¸¾Ò½À´Ï´Ù.

ÇöÀç endoscopic atrophy´Â Kimura-Takemoto classificationÀ» »ç¿ëÇÏ¿© ºÐ·ù¸¦ ÇÏ°í Àִµ¥, ÀÌ´Â H. pylori associated gastritis¿¡¼­ÀÇ ºÐ·ùÀÌ°í, autoimmune gastritis¿¡ ´ëÇؼ­´Â endoscopic atrophy¸¦ ³ª´©´Â ±âÁØÀÌ ¾ø½À´Ï´Ù. ±×·¡¼­, atrophy scoringÀ» À§ÇØ bodyÀÇ lesser curvature¿Í greater curvature °¢°¢ÀÇ atrophy Á¤µµ¿¡ µû¶ó 1Á¡ºÎÅÍ 4Á¡±îÁö, fundus´Â atrophy°¡ ÀÖÀ¸¸é 1Á¡, ¾øÀ¸¸é 0Á¡À¸·Î ÇÏ¿© scoringÀ» Çؼ­ ÇÕ»êÇÏ¿© Á¤¸®ÇÏ¿´½À´Ï´Ù. Æò±Õ ÃßÀû °üÂû ±â°£Àº 7.8³â, ³»½Ã°æ »ó¿¡¼­ advanced corporal atrophy (reverse atrophy) ±îÁö °É¸®´Â ½Ã°£Àº Æò±Õ 2.2³â Á¤µµ °É·È½À´Ï´Ù. ƯÈ÷, Èï¹Ì·Î¿ü´ø °á°ú´Â H. pylori °¨¿°ÀÌ ÀÖ´Â ±º°ú ¾ø´Â ±ºÀ¸·Î ³ª´©¾î Á¡¼ö¸¦ ºñ±³ÇØ º¸¾ÒÀ» ¶§ advanced corporal atrophy±îÁö °É¸®´Â ½Ã°£ÀÌ H. pylori ¿¡ °¨¿°µÈ ±º¿¡¼­ ´õ ¿À·¡ °É·È´Ù´Â °ÍÀÔ´Ï´Ù (2 years vs. 3.67 years, p=0.007). Gastrin ¼öÄ¡´Â ´õ ³·¾Ò½À´Ï´Ù (599.7 pg/ml vs. 215.8 pg/ml, p=0.019). ÀÌ·¯ÇÑ °á°ú¿¡¼­ À¯ÃßÇØ º¸¸é, H. pylori´Â colonizationÀ» À§ÇØ À§ Á¡¸·ÀÇ immunity¸¦ Á¶ÀýÇÔÀ¸·Î½á atrophy¸¦ ´ÊÃß·Á°í ÇÏ´Â °Ç ¾Æ´ÑÁö ÇÏ´Â »ý°¢ÀÌ µé¾ú½À´Ï´Ù. (Conclusion: In AIG patients, infection with H. pylori may affect the rate of atrophy progression.)

¿©·¯ º¯¼ö¿Í °üÂûÀÚ °£ÀÇ ÀÏÄ¡µµ µî bias°¡ ¸¹Àº ¿¬±¸ÀÌ°í, Åë°èÀûÀ¸·Î³ª °üÂûÇÑ È¯ÀÚ ¼öµµ ¸¹ÀÌ ºÎÁ·ÇÑ ³»¿ëÀÌÁö¸¸, autoimmune gastritis ȯÀÚµéÀÇ °ú°Å ³»½Ã°æ ¼Ò°ßÀ» º¸¸é¼­ ²À ÇѹøÀº Á¤¸®ÇØ º¸°í ½Í¾î¼­ À̹ø¿¡ ¹ßÇ¥ÇÏ°Ô µÇ¾ú½À´Ï´Ù. ¾à 3°³¿ù °£ »õ·Î¿î º´¿øÀ¸·Î ¿Å°Ü ȯÀÚµéÀ» º¸´Âµ¥, ÇöÀç±îÁö 4¸íÀÇ autoiummune gastritis ȯÀÚ¸¦ Áø´ÜÇÏ°Ô µÇ¾ú½À´Ï´Ù. Ç÷û°Ë»ç¿Í ³»½Ã°æ, Á¶Á÷°Ë»ç·Î À̾îÁö´Â Áø´Ü ¹æ¹ýÀ¸·Î autoimmune gastritis°¡ Àß Áø´Ü µÇ¾î, Ä¡·á¹ýÀ̳ª ¸íÈ®ÇÑ management°¡ ¾ÆÁ÷ ¾ø¾îµµ ȯÀÚµéÀÇ À§Àå°ü Áõ»óÀ̳ª Áß¿ä ¿µ¾ç¼Ò °áÇÌ, µ¿¹ÝµÈ ÀÚ°¡¸é¿ª Áúȯ µîÀÌ Áø´Ü°ú ÇÔ²² Àß °ü¸®µÇ¾úÀ¸¸é ÇÏ´Â ¹Ù·¥ÀÔ´Ï´Ù."

Àúµµ KDDW2023¿¡ À§Á¾¾ç ȯÀÚ¿¡¼­ antiparietal cell antibodyÀÇ ÀÓ»óÀû ÀÇÀÇ¿¡ ´ëÇÑ Æ÷½ºÅ͸¦ ¹ßÇ¥ÇÏ¿´½À´Ï´Ù.

PDF


3. ¿ì¸®³ª¶óÀÇ Ã¹ ÀÚ°¡¸é¿ªÀ§¿° case series (2021, °Ç±¹´ë À̼±¿µ ±³¼ö´Ô)

ÀÚ°¡¸é¿ª¼º À§¿°Àº À¯·´, ƯÈ÷ ºÏÀ¯·´¿¡ ¸¹°í ´Ù¸¥ °÷¿¡¼­´Â µå¹°´Ù°í ¾Ë·ÁÁ® ÀÖ¾ú½À´Ï´Ù. 2008³âÆÇ º´¸®ÇРå¿¡´Â ¾Æ·¡¿Í °°ÀÌ ¾²¿© ÀÖ½À´Ï´Ù. ÀÌ ¶§¹®¿¡ ¿ì¸®³ª¶ó¿¡¼­´Â ¹«½ÃµÇ¾î ¿Ô½À´Ï´Ù.

°Ç±¹´ë À̼±¿µ ±³¼ö´Ô²²¼­ 6°³¿ù µ¿¾È ¿Ü·¡¸¦ ¹æ¹®ÇÑ È¯ÀÚ Áß H. pylori °¨¿°°ú ¹«°üÇÏ°Ô Ã¼ºÎ ¿ì¼¼Çü À§Ãà°ú ³·Àº Ç÷û PG I ¼öÄ¡, ³ôÀº °¡½ºÆ®¸°¼öÄ¡¸¦ º¸ÀÎ °æ¿ì¿¡ Ç÷û Ç׺®¼¼Æ÷ Ç×ü¸¦ °Ë»çÇÑ °á°ú, 5¸í¿¡¼­ ÀÚ°¡¸é¿ª¼º À§¿°À» ¹ß°ßÇÏ°í º¸°íÇÏ¿´½À´Ï´Ù (´ëÇÐÇ︮ÄÚ¹ÚÅÍÇÐȸÁö 2021)

Serum gastrinÀÇ º¯È­µµ Helicobacterd¿¡ ÀÇÇÑ BÇü À§¿°°ú´Â Á¶±Ý ´Ù¸¥ ¾ç»óÀ» º¸Àδٰí ÇÕ´Ï´Ù.


4. ÀÚ°¡¸é¿ª¼º À§¿°ÀÇ ÀÓ»ó»ó

¶Ñ·ÇÇÑ pernicious anemia »Ó ¾Æ´Ï¶ó ö°áÇ̼º ºóÇ÷µµ ÈçÇÕ´Ï´Ù. Ç÷¾×°Ë»ç¿¡¼­ vitamin B12³ª ironÀÌ Á¤»ó¹üÀ§¸¦ º¸ÀÌ´õ¶óµµ nutritional deficiency »óÅÂÀÏ ¼ö ÀÖ½À´Ï´Ù.

Delayed gastric emptyingÀ̳ª functional esophageal disorder¸¦ º¸ÀÏ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·± °æ¿ì PPI¸¦ »ç¿ëÇϸé Áõ»óÀÌ ¾ÇÈ­µÇ±âµµ ÇÕ´Ï´Ù.

Ç︮ÄÚ¹ÚÅÍ Á¦±ÕÄ¡·á ÈÄ È£±â°Ë»ç¸¦ ½ÃÇàÇϸé endless eradication failure¸¦ º¸ÀÌ´Â °æ¿ì°¡ ÀÖ½À´Ï´Ù. Urease producing non-Helicobacter °¨¿°ÀÌ µ¿¹ÝµÇ±â ¶§¹®ÀÔ´Ï´Ù. µû¶ó¼­ ÀÚ°¡¸é¿ª¼º À§¿° ȯÀÚ¿¡¼­ Ç︮ÄÚ¹ÚÅÍ Á¦±ÕÄ¡·á ÈÄ stool antigen test°¡ ´õ À¯¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù.


5. ÀÚ°¡¸é¿ª¼º À§¿°°ú ½Å°æ³»ºÐºñ Á¾¾ç

ÀÚ°¡¸é¿ª¼º À§¿° ȯÀÚ¿¡¼­ ¹ß°ßµÇ¾î ESD·Î Ä¡·áÇÑ ½Å°æ³»ºÐºñÁ¾¾ç


6. ÀÚ°¡¸é¿ª¼º À§¿°°ú À§¾Ï

ÀÚ°¡¸é¿ª¼º À§¿°¿¡¼­ ½Å°æ³»ºÐºñÁ¾¾çÀÌ È£¹ßÇÑ´Ù´Â °ÍÀº ¸í¹éÇÑ »ç½ÇÀÔ´Ï´Ù. ±×·±µ¥ À§¾Ïµµ ¸¹ÀÌ ¹ß»ýÇϴ°¡¿¡ ´ëÇؼ­´Â ³í¶õÀÌ ÀÖ½À´Ï´Ù.

2023³â ¹ßÇ¥µÈ À¯·´ÀÇ °üÂû¿¬±¸(Rugge. Gut 2023)¿¡ ÀÇÇϸé Ç︮ÄÚ¹ÚÅÍ°¡ ¾ø´Â ÀÚ°¡¸é¿ª¼º À§¿°¿¡¼­ À§¾ÏÀÇ ¹ß»ý·üÀÌ Áõ°¡ÇÏÁö ¾Ê´Â´Ù°í ÇÕ´Ï´Ù.

"Compared with the general population, corpus-restricted inflammation/atrophy does not increase the GC risk. The excess of GC risk reported in patients with AIG could plausibly result from unrecognised previous/current H. pylori comorbidity."

Ç︮ÄÚ¹ÚÅÍ °¨¿°°ú ÀÚ°¡¸é¿ª¼º À§¿° »çÀÌÀÇ °ü°è´Â ¾ÆÁ÷ ºÒÅõ¸íÇÕ´Ï´Ù. Ç︮ÄÚ¹ÚÅÍ°¡ ÀÚ°¡¸é¿ª¼º À§¿°ÀÇ ¿øÀÎÀ̶ó´Â ÁÖÀåµµ ÀÖ°í, ¹Ý´ë·Î ÀÚ°¡¸é¿ª¼º À§¿°À» ¾ïÁ¦ÇÑ´Ù´Â ÁÖÀåµµ ÀÖ½À´Ï´Ù. Ç︮ÄÚ¹ÚÅÍ°¡ ¾ø´Â ÀÚ°¡¸é¿ª¼º À§¿°Àº complete intestinal metaplasia (incomplete°¡ ¾Æ´Ô¿¡ À¯ÀÇ)¿Í pseudopyloric metaplasia¿¡¼­ ¸ØÃß°í ¾ÏÀº ¹ß»ýÇÏÁö ¾Ê´Â °Í °°½À´Ï´Ù.

Goldenring Gut 2023

ÀÚ°¡¸é¿ª¼º À§¿° ȯÀÚµµ Ç︮ÄÚ¹ÚÅÍ °¨¿°À» °¡Áö´Â °æ¿ì°¡ ÀÖ½À´Ï´Ù. ÀÌ °æ¿ì¿¡´Â À§¾Ï ¹ß»ý °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù. ÀÚ°¡¸é¿ª¼º À§¿° ȯÀÚ¿¡¼­µµ Ç︮ÄÚ¹ÚÅÍ °¨¿° ¿©ºÎ¸¦ È®ÀÎÇÏ°í ÇÊ¿äÇϸé Á¦±ÕÄ¡·á¸¦ ÇØ ÁÖ´Â °ÍÀÌ ÁÁ°Ú½À´Ï´Ù.

ÀÚ°¡¸é¿ª¼º À§¿° ȯÀÚ¿¡¼­ PPI¸¦ Àå±â º¹¿ëÇÑ °æ¿ì À§¾ÏÀÇ ¹ß»ý·üÀÌ ³ô´Ù´Â ¿¬±¸µµ ÀÖ½À´Ï´Ù

[2023-8-24] Á¦ ¿Ü·¡¿¡ ³»¿øÇÑ À§¾ÏÀ̳ª À§¼±Á¾ ȯÀÚ¿¡¼­ antiparietal antibody ¾ç¼º·üÀº 6.5%¿´½À´Ï´Ù. À̵é Áß »ó´ç¼ö´Â anti-Helicobacter antibodyµµ ¾ç¼ºÀ̹ǷΠanti-parietal antibodyÀÇ ¿ªÇÒÀ» ¸íÈ®È÷ ±Ô¸íÇϱâ´Â ¾î·Æ½À´Ï´Ù. Á¦¹ý Áß¿äÇÑ Àǹ̰¡ ÀÖÀ» °ÍÀ¸·Î ÃßÁ¤ÇÏ°í ¿¬±¸ ÁßÀÔ´Ï´Ù.


7. ÀÚ°¡¸é¿ªÀ§¿°°ú µ¿¹ÝµÇ´Â Áúȯ - °©»ó¼±Áúȯ µî

ÀÚ°¡¸é¿ªÀ§¿°°ú ¸î °¡Áö ¸î °¡Áö ÀÚ°¡¸é¿ªÁúȯÀÌ µ¿¹ÝµË´Ï´Ù.

ÀÚ°¡¸é¿ª¼º À§¿° ȯÀÚ¿¡¼­ °©»ó¼± ÁúȯÀÌ ÈçÇÕ´Ï´Ù. Thyro-entero-gastric autoimmunity¶ó´Â °³³äÀ¸·Î ¼³¸íµÇ°í ÀÖÀ¸¸ç autoimmune polyglandular syndromeÀ̶ó´Â ¸»µµ ÀÖ½À´Ï´Ù.


[2023-11] ÀÚ°¡¸é¿ª¼º À§¿° ȯÀÚÀÇ °©»ó¼± °Ë»ç¿¡ ´ëÇÑ °¡À̵å¶óÀÎÀÌ ¾ø½À´Ï´Ù. ÀÏ´Ü ¾Æ·¡¿Í °°Àº full workupÀ» ½ÃÇàÇØ º¼ ¼ö ÀÖ´Ù°í »ý°¢µË´Ï´Ù.

±×¸®°í anti-intrinsic factor antibody´Â BL5079·Î ½ÃÇàÇÒ ¼ö ÀÖ½À´Ï´Ù. ±Þ¿© 9,790¿ø


[FAQs]

[2022-3-3. Çлý Áú¹®]

±³¼ö´Ô, ¾È³çÇϼ¼¿ä. ¼º±Õ°ü´ëÇб³ ÀÇ°ú´ëÇÐ º»°ú 2Çгâ ÇлýÀÔ´Ï´Ù. ±³¼ö´ÔÀÇ À§¿° °­ÀǸ¦ µè°í ÇÑ °¡Áö Áú¹®ÀÌ ÀÖ¾î ¸ÞÀÏ µå¸³´Ï´Ù.

Atrophic gastritis¸¦ ºÐ·ùÇÏ´Â ±âÁØÀÎ Kimura classification¿¡ µû¸£¸é antrum(ÀüÁ¤ºÎ)À» ±âÁØÀ¸·Î À§Ã¼ºÎ ¼Ò¸¸±îÁö¸¸ atrophy°¡ ÀÖÀ¸¸é Åë»óÇü(closed type)ÀÌ°í, ±âÀúºÎ¿Í À§Ã¼ºÎ ´ë¸¸±îÁö atrophy°¡ È®ÀåµÇ¸é À§ÃàÇü(open type)ÀÔ´Ï´Ù.

ÇÏÁö¸¸ autoimmune disease¿¡ ÀÇÇؼ­ ¹ß»ýÇÏ´Â diffuse corporal atrophic gastritis (type A atrophic gastritis)´Â À§»êÀ» ºÐºñÇÏ´Â parietal cellÀÌ ÁÖ·Î À§Ã¼ºÎ³ª ±âÀúºÎ¿¡ ¸¹¾Æ¼­ ÀÌÂÊ¿¡¸¸ atrophy°¡ »ý±â´Â °æ¿ìµµ Àִµ¥¿ä, ÀÌ °æ¿ì´Â Kimura classification¿¡¼­ ¾î¶»°Ô ºÐ·ùµÇ´Â °Ç°¡¿ä?

[2022-3-3. ÀÌÁØÇà ´äº¯]

ÁÁÀº Áú¹®ÀÔ´Ï´Ù. Kimura ºÐ·ù´Â ¿À·¡ Àü ÀϺ»¿¡¼­ ¸¸µé¾îÁø ºÐ·ù¹ýÀε¥ ÀÚ°¡¸é¿ª¼º À§¿°Àº °í·ÁµÇÁö ¾Ê¾Ò½À´Ï´Ù. ´ëºÎºÐ Helicobacter¿Í °ü·ÃµÈ type B atrophic gastritis¿¡ Kimura ºÐ·ù¸¦ Àû¿ëÇÑ´Ù°í »ý°¢ÇϽñ⠹ٶø´Ï´Ù.

¾È¿ëȯ ¿øÀå´Ô 2022-2-10 HOPE EndoTODAY ³»½Ã°æ ¼¼¹Ì³ª

[2023-4-15. Ãá°è ³»½Ã°æ ±³½Ç ÈÄ Áú¹®]

ÀÚ°¡¸é¿ª¼º À§¿°ÀÌ »ý¼ÒÇؼ­ EndoTODAY¸¦ º¸°í °øºÎÇÏ´Ù ±Ã±ÝÇÑ Á¡ÀÌ »ý°å½À´Ï´Ù. Ưº°ÇÑ Ä¡·á°¡ ¾ø´Â °Í °°Àºµ¥, ȯÀÚ¸¦ Áö¼ÓÀûÀ¸·Î f/u Çϸ鼭 nutritional statement Æò°¡ & ÇÊ¿ä ½Ã º¸Ãæ°ú NET ¹ß°ßÀ» À§ÇÑ EGD¸¦ ½ÃÇàÇÏ¸é µÇ´Â °É±î¿ä? ±×·³ ÀÌ °æ¿ì¿¡ EGD´Â ¾ó¸¶ °£°ÝÀ¸·Î ½ÃÇàÇÏ¸é µÉ±î¿ä?

Urease-producing non-helicobacter bacteria °¨¿°ÀÌ µ¿¹ÝµÇ´Âµ¥ ÀÌ°ÍÀº ³ô¾ÆÁø pH ¶§¹®Àΰ¡¿ä? ±×¸®°í ÀÌ Ä£±¸µéÀº Ä¡·á°¡ ÇÊ¿äÇÏÁö ¾Ê´ÂÁö¿ä? ¿¹¸¦µé¾î ¾î·µç ¼¼±Õ °¨¿°ÀÌ´Ï±î °¨¿° ½Ã cancer risk°¡ ¿Ã¶ó°¡°Å³ª ÇÏÁö ¾ÊÀ»±î Çؼ­ ¿©ÂÞ¾î º¾´Ï´Ù.

[2023-4-16. ÀÌÁØÇà ´äº¯]

¾È¿ëȯ ¼±»ý´ÔÀÇ °­ÀǸ¦ ²À º¸½Ã±â ¹Ù¶ø´Ï´Ù.

- Áú¹®°ú ´äº¯ 2022-10-12. ¾È¿ëȯ ¿øÀå´Ô

¿ì¸®³ª¶ó¿¡¼­ ÀÚ°¡¸é¿ª¼º À§¿°Àº underestimation µÇ°í ÀÖ½À´Ï´Ù. NET ȯÀÚ Áß ÀϺΰ¡ ÀÚ°¡¸é¿ª¼º À§¿°ÀÏ °ÍÀ¸·Î »ý°¢µË´Ï´Ù. ±×¸®°í À§¾Ï Áß ÀϺεµ ÀÚ°¡¸é¿ª¼º À§¿°°ú °ü·ÃÀÌ ÀÖÁö ¾ÊÀ»±î ÃßÁ¤ÇÕ´Ï´Ù.

ÀÚ°¡¸é¿ª¼º À§¿°¿¡¼­ À§¾ÏÀ̳ª NET °ËÁøÀº 1³â¿¡ Çѹø À§³»½Ã°æÀ̸é ÃæºÐÇÒ °ÍÀ¸·Î »ý°¢ÇÕ´Ï´Ù. ´Ù¸¥ °ÍÀº º°·Î ÇÒ °ÍÀÌ ¾ø½À´Ï´Ù. ¾ÆÁÖ µå¹°°Ô megalobastic anemia°¡ ¿Ã ¼ö ÀÖ´Ù°í ÇÕ´Ï´Ù.

ÀÚ°¡¸é¿ª¼º À§¿°¿¡¼­ Ç︮ÄÚ¹ÚÅÍ UBT °Ë»ç À§¾ç¼ºÀÌ °¡´ÉÇÕ´Ï´Ù. Urease-producing non-helicobacter bacteriaÀÏ °ÍÀä, ¾ÆÁ÷ À̵鿡 ´ëÇÑ ±¸Ã¼ÀûÀÎ Ä¡·á¹ýÀº È®¸³µÇ¾î ÀÖÁö ¾Ê½À´Ï´Ù.


[2023-6-14] ¼øõ ¾ÆÀ̹ÌÄÚº´¿ø (úÞ ºÎõ ´õ¸¸Á·º´¿ø) ¾È¿ëȯ ¿øÀå´Ô²²¼­ ÀÚ°¡¸é¿ª¼º À§¿°¿¡ ´ëÇÑ µÎ¹ø° ³í¹®À» º¸³»Áּ̽À´Ï´Ù.

PDF 2.1M

¾Æ·¡´Â ÀúÀÚ²²¼­ Á÷Á¢ ³í¹®À» ¼Ò°³ÇÑ ³»¿ëÀÔ´Ï´Ù.

"À̹ø Áõ·Ê´Â ÇϳªÀÇ Áõ·Ê ¾È¿¡ ¸î °¡Áö Àǹ̸¦ ´ã°íÀÚ ¿å½ÉÀ» ºÎ·È½À´Ï´Ù.

À̹ø Áõ·Ê¿¡¼­ ´Ù·ç°íÀÚ Çß´ø ù¹ø° ³»¿ëÀº ÀÚ°¡¸é¿ª¼ºÀ§¿°ÀÇ stage ÀÔ´Ï´Ù. ÀϺ»¿¡¼­´Â early stageÀÇ ÀÚ°¡¸é¿ª¼ºÀ§¿°ÀÌ ¸¹ÀÌ º¸°íµÇ°í ÀÖ½À´Ï´Ù¸¸, ³»½Ã°æ ¼Ò°ßº¸´Ù´Â Ç÷û°Ë»ç¿Í Á¶Á÷°Ë»ç¸¦ ¹ÙÅÁÀ¸·Î Áø´ÜÀÌ ÀÌ·ç¾îÁ®¾ß ÇϹǷΠ¿ì¸®³ª¶ó¿¡¼­´Â ½±Áö ¾ÊÀº °Í °°½À´Ï´Ù. À̹ø Áõ·Ê¿¡¼­µµ ÀüÇüÀûÀÎ advanced stageÀÇ corpus dominant atrophy¸¦ º¸À̱â Àü, üºÎ Á¡¸·ÀÇ ºÒ±ÔÄ¢ÇÑ º¯È­¿Í Á¶Á÷°Ë»ç, Ç÷û°Ë»ç µîÀ» ¹ÙÅÁÀ¸·Î ongoing stage¿¡¼­ Áø´ÜµÈ Áõ·Ê·Î, ÀÚ°¡¸é¿ª¼ºÀ§¿°Àº progressive ÇÑ ÁúȯÀ̶ó´Â °ÍÀ» ÀÌÇØÇÏ°í °Ë»çÇؾßÇÑ´Ù´Â °ÍÀ» °­Á¶ÇÏ°í ½Í¾ú½À´Ï´Ù.

In the present case, erythematous nodules and atrophic mucosa were observed together in the gastric body, but inflammatory cell infiltration and ECL cell hyperplasia were more severe in the atrophic mucosa than in erythematous nodules... AIG is a progressive inflammatory disease that can appear as various features on endoscopy depending on its stage, and show ambig uous serologic results, thus biopsy should be performed even if widespread atrophy is not apparent, and remnant oxyntic mucosal lesions mixed with atrophic mucosa and flattened folds are observed in the gastric body.

µÎ ¹ø°·Î À̹ø Áõ·Ê´Â »óÇÇÇÏÁ¾¾çÀÌ µ¿¹ÝµÈ ÀÚ°¡¸é¿ª¼ºÀ§¿° ȯÀÚ¿´½À´Ï´Ù. ÃÖ±Ù ¿©·¯ ¼¼¹Ì³ª¿¡¼­ »óÇÇÇÏÁ¾¾ç¿¡ ´ëÇÑ °­ÀÇ°¡ ´Ù·ïÁö°í ÀÖÁö¸¸, ¾ÆÁ÷µµ »óÇÇÇÏ Á¾¾ç¿¡ ´ëÇÑ management´Â ¹Ì±¹, À¯·´, ÀϺ» ¸ðµÎ Á¶±Ý¾¿ ´Ù¸¥ Á¢±Ù¹ýÀ» º¸ÀÌ°í ÀÖ½À´Ï´Ù. ƯÈ÷, ÀÚ°¡¸é¿ª¼ºÀ§¿°Àº neuroendocrine tumor (NET) ¹ß»ýÀÌ ³ôÀº Ư¡À» °¡Áö°í ÀÖ´Â ÁúȯÀ¸·Î, NETÀÇ ¿øÀÎÀÌ µÇ´Â ECL cellÀÌ deep epithelium¿¡ À§Ä¡ÇÏ°í ÀÖ¾î NET°¡ »óÇÇÇÏÁ¾¾çó·³ º¸ÀÏ ¼öµµ Àֱ⠶§¹®¿¡ ÀÚ°¡¸é¿ª¼ºÀ§¿° ȯÀÚ¿¡¼­ °üÂûµÇ´Â Á¡¸·ÇÏ Á¾¾çÀº Á¢±Ù¹æ½ÄÀÌ Á» ´Þ¶ó¾ß ÇÏÁö ¾ÊÀ»±î¶ó´Â Áú¹®À» ´øÁ®º¸°í ½Í¾ú½À´Ï´Ù. ¸¶Áö¸·À¸·Î, ÀÚ°¡¸é¿ª¼ºÀ§¿°ÀÇ °æ¿ì NET°¡ ¾Æ´Ï´Ù ÇÏ´õ¶óµµ ´Ù¾çÇÑ Á¾·ùÀÇ »óÇÇÇÏ Á¾¾çÀÌ µ¿¹ÝµÉ ¼ö ÀÖ°í, trophic action À» °¡Áö°í ÀÖ´Â hypergastrinemia¸¦ º¸ÀÌ´Â ÁúȯÀ̱⠶§¹®¿¡, ÇÔ²² µ¿¹ÝµÈ »óÇÇÇÏ Á¾¾ç¿¡ ´ëÇÏ¿© hypergastrinemia°¡ ¾î¶² ¿µÇâÀ» ÁÙ ¼ö ÀÖÀ»Áö, ÀÌ¿¡ ´ëÇÑ Ãß°¡ÀûÀÎ °í¹Îµµ ÇغÃÀ¸¸é ÁÁ°Ô´Ù´Â Àǹ̸¦ ´ãÀ¸·Á°í ÇÏ¿´½À´Ï´Ù. ÇϳªÀÇ Áõ·Ê¿¡ ÀÌ·¸°Ô ¿©·¯ ³»¿ëÀ» ´ã¾Æ º¸·Á°í Çß´õ´Ï ³»¿ëÀÌ ¸¹ÀÌ ¹ÌÈíÇÕ´Ï´Ù¸¸, ÀÚ°¡¸é¿ª¼ºÀ§¿°¿¡ ´ëÇÏ¿© ÀÌ·¯ÇÑ ºÎºÐµéÀÌ °í·ÁµÇ¾úÀ¸¸é ÁÁ°Ú°í, ¹Ý´ë·Î »óÇÇÇÏ Á¾¾ç¿¡ ´ëÇÑ Á¢±ÙÀ» ÇÒ¶§ µ¿¹ÝµÈ À§ »óÅ¿¡ ´ëÇÑ Æò°¡¸¦ ²À ÇÔ²² ÇØ¾ß ÇÒ °ÍÀ¸·Î »ç·áµË´Ï´Ù.

ȯÀÚ¸¦ ÅëÇؼ­ ¹è¿ì°í Ç×»ó °øºÎÇÏ´Â ¸¶À½À¸·Î ÇÑ °ÉÀ½¾¿ ¶Ç Çغ¸·Á°í ÇÕ´Ï´Ù. ±×¸®°í, ¼ÒÁßÇÑ ±³¼ö´Ô°úÀÇ Àο¬À¸·Î ÀÌ·¸°Ô ¸ÞÀÏÀ» º¸³¾¼ö ÀÖ¾î ÇູÇÏ°í °¨»çÇÕ´Ï´Ù."

°³¾÷°¡¿¡¼­ Áø·áÇϽø鼭 »õ·Î¿î Áúº´¿¡ ´ëÇÏ¿© °øºÎÇÏ°í ÀڷḦ ¸ð¾Æ ³í¹®À» ³½´Ù´Â °ÍÀº ´ë´ÜÇÑ ÀÏÀ̶ó°í »ý°¢ÇÕ´Ï´Ù. ¾È¿ëȯ ¿øÀå´Ô. Á¤¸» ¼ö°í ¸¹À¸¼Ì°í °¨»çÇÕ´Ï´Ù.

¸¶Áö¸·À¸·Î ÀÚ°¡¸é¿ª¼º À§¿° ¹× °ü·Ã Áúȯ (carcinoid, pyloric gland adenoma µî)¿¡ ´ëÇÑ ÇÑ º´¸®ÇÐÀÚÀÇ »ó¼¼ÇÑ ¼³¸í YouTube µ¿¿µ»óÀ» ¼Ò°³ÇÕ´Ï´Ù.


[2023-8-29] ÀÚ°¡¸é¿ª¼º À§¿° ȯÀÚ°¡ ÀÚÁÖ ¹ß°ßµÇ¾î ȯÀÚ ¼³¸í¼­¸¦ ¸¸µé¾ú½À´Ï´Ù.

ÀÚ°¡¸é¿ª¼º À§¿°Àº ¾ÆÁ÷±îÁö ¿øÀÎÀÌ ¹àÇôÁöÁö ¾ÊÀº ÁúȯÀÔ´Ï´Ù. À§Á¡¸· Áß À§»êÀ» ºÐºñÇÏ´Â ºÎÀ§°¡ ¾ã¾ÆÁö´Â ÇüÅÂ, Áï AÇü À§Ã༺À§¿°ÀÌ Æ¯Â¡ÀÔ´Ï´Ù. À¯¾ÏÁ¾, °úÇü¼º ¿ëÁ¾, À§¾ÏÀÇ ¹ß»ý·üÀÌ ÀϹÝÀκ¸´Ù ³ôÀ¸¹Ç·Î 1³â¿¡ Çѹø ³»½Ã°æ °Ë»ç°¡ ÇÊ¿äÇÕ´Ï´Ù. ½ÉÇØÁö¸é ºóÇ÷À̳ª ¸î °¡Áö ¿µ¾ç¼Ò °áÇÌÁõÀÌ ³ªÅ¸³¯ ¼ö ÀÖ½À´Ï´Ù. °©»ó¼±±â´ÉÀúÇÏÁõÀÌ ¹ß»ýÇϱ⵵ ÇÕ´Ï´Ù.

´Ù¸¥ µ¿¹Ý Áõ»óÀº ¾øÀ¸¹Ç·Î Åõ¾àÀ» ±ÇÇÏ´Â »óȲÀº ¾Æ´Ï¸ç »ó½Ä¿¡ ÁØÇÑ °Ç°­ÇÑ ½Ä»ýÈ°°ú 1³â ÈÄ Ç÷¾×°Ë»ç, ³»½Ã°æÀ» ±ÇÇÕ´Ï´Ù. ºñ½ÎÁö ¾ÊÀº Á¾ÇÕºñŸ¹Î ÇÑ °¡Áö Á¤µµ¸¦ µå½Ã´Â °ÍÀº ³ª»ÚÁö ¾ÊÀ» °Í °°½À´Ï´Ù.


[2023-11] ÀÚ°¡¸é¿ª¼º À§¿° ȯÀÚÀÇ °©»ó¼± °Ë»ç¿¡ ´ëÇÑ °¡À̵å¶óÀÎÀÌ ¾ø½À´Ï´Ù. ÀÏ´Ü ¾Æ·¡¿Í °°Àº full workupÀ» ½ÃÇàÇØ º¼ ¼ö ÀÖ´Ù°í »ý°¢µË´Ï´Ù.

±×¸®°í anti-intrinsic factor antibody´Â BL5079·Î ½ÃÇàÇÒ ¼ö ÀÖ½À´Ï´Ù. ±Þ¿© 9,790¿ø


[2022-12-1. ¼øõ Ç÷¯½º ¾ÆÀ̹ÌÄÚ ¾È¿ëȯ ¿øÀå´Ô (´ëÇÑ ÀÚ°¡¸é¿ª¼ºÀ§¿° ¿¬±¸È¸) ÆíÁö]

ÀÌÁØÇà ±³¼ö´Ô²².

±³¼ö´Ô ¾È³çÇϼ̽À´Ï±î? ³¯ÀÌ ¸¹ÀÌ Ãß¿öÁ³½À´Ï´Ù.

Àü¿¡ Àá±ñ ¸»¾¸µå·È´ø, ÀÚ°¡¸é¿ª¼º À§¿° ȯÀÚ¿¡ ´ëÇÑ Áõ·Ê ³í¹®ÀÌ ³ª¿Í¼­ ÀÌ·¸°Ô º¸³»µå¸³´Ï´Ù. ¸¹ÀÌ ºÎÁ·ÇÏ¿© ¿©·¯¹øÀÇ ¼öÁ¤°ú ±³Á¤À» °ÅÄ¡°í ¸¹Àº µµ¿òÀ» ¹Þ¾Æ¼­ ÀÌ·¸°Ô ³ª¿À°Ô µÇ¾ú½À´Ï´Ù.

A Graves' disease patient diagnosed as autoimmune gastritis with Helicobacter pylori infection. PDF 1M.

À۳⠱³¼ö´Ô°ú webinar¸¦ ÇÔ²² Çϸ鼭 À̼±¿µ±³¼ö´ÔÀ» ÅëÇØ Áúȯ¿¡ ´ëÇÑ ¾ê±â¸¦ µé¾ú°í, Áø·á Áß¿¡ Áø´ÜµÈ ȯÀÚµé°ú ÇÔ²² °øºÎÇϱ⠽ÃÀÛÇÏ¿© ÃÖ±Ù±îÁö ³²ÀÚ È¯ÀÚ Æ÷ÇÔ 22¸íÀÇ È¯ÀÚ¸¦ º¸°í ÀÖ½À´Ï´Ù. (1³â 7°³¿ù, ¾à 0.9% ÀÔ´Ï´Ù.) À̹ø Áõ·Ê´Â H. pylori-associated À§¿°ÀÌ µ¿¹ÝµÇ¾î ÀÖ¾î Ç÷ûÇÐÀû °Ë»ç Áß Æé½Ã³ë°Õ I ¼öÄ¡°¡ ³ô¾Æ ´Ù¼Ò Áø´ÜÀÌ ¾î·Á¿üÁö¸¸, µ¿¹ÝµÈ ÀÚ°¡¸é¿ª°©»ó¼±Áúȯ°ú üºÎ atrophy°¡ ½ÉÇÑ °ÍÀ» Åä´ë·Î Àû±ØÀûÀ¸·Î Á¶Á÷°Ë»ç¸¦ ½ÃÇàÇÏ¿´°í, µ¿½Ã¿¡ ÁøÇàÇÑ Ãß°¡ Ç÷û°Ë»ç¿¡¼­ hypergastrinemia, anti-parietal cell antibody ¾ç¼ºÀ¸·Î Áø´ÜÀÌ °¡´ÉÇÏ¿´½À´Ï´Ù.

¿ì¸®³ª¶ó¿¡¼­ ÀÚ°¡¸é¿ª¼º À§¿°Àº overlook µÇ¾î ÀÖ´Â µí ÇÕ´Ï´Ù. H. pylori °¨¿°°ú ¹«°üÇÏ°Ô reverse advanced atrophy°¡ ÀǽɵǸé, body¿Í antrum °¢°¢¿¡¼­ Á¶Á÷°Ë»ç¸¦ ½ÃÇàÇÏ°í (update Sydney systemÀ¸·Î ÇÏ¸é ´õ ÁÁ½À´Ï´Ù¸¸..), chromogranin A °Ë»ç¸¦ ÇÔ²² ½ÃÇàÇÏ¿© (ÀúÈñ º´¿ø ±âÁØ, ȯÀÚ º»Àκδã±ÝÀº ¾à 17,000~18,000¿øÁ¤µµ ÀÔ´Ï´Ù), atrophic gastritis¸¦ documentation ÇÔ°ú µ¿½Ã¿¡ body¿¡¼­ ECL cellÀÇ hyperplasia¸¦ È®ÀÎ ÇÏ¸é º¸´Ù Á¤È®ÇÑ Áø´ÜÀ» ÇÒ ¼ö ÀÖÀ» °Í °°½À´Ï´Ù. ¶ÇÇÑ, ȯÀÚ°¡ Ç÷¾×°Ë»ç¸¦ ÇÒ ¼ö ÀÖ´Ù¸é Ç÷ûÇÐÀû °Ë»ç Áß gastrin, anti-parietal cell antibody, pepsinogen test (I, II, I/II ratio)¸¦ ÇÔ²² check Çغ¸¸é ´õ¿í È®½Ç ÇÒµí ½Í½À´Ï´Ù. ¹°·Ð, H. pylori IgG antibodyµµ ÃøÁ¤Çϸé ÁÁ°ÚÁö¸¸ ȯÀںδã 90%¿¡´Ù°¡ Áø´Ü clue´Â ¾Æ´Ï¹Ç·Î Àú´Â H. pylori°¡ ÀǽɵǸé (spotty redness, nodular gastritis) CLOtest³ª Á¶Á÷°Ë»ç Giemsa stainÀ» ÀÇ·Ú ÇÏ°í ÀÖÀ¸¸ç, ²À ÇÊ¿äÇÑ °æ¿ì ȯÀÚÀÇ µ¿ÀǸ¦ ±¸ÇÏ°í antibody¸¦ ÃøÁ¤ÇÏ°í ÀÖ½À´Ï´Ù.

ÇÑÇظ¦ º¸³»´Â ¸¶Á÷¸· ´Þ, ±³¼ö´Ô°úÀÇ ¼ÒÁßÇÑ Àο¬À» ÅëÇØ ÀÌ·¸°Ô ÀÛÀº °á½ÇÀ» ¸Î°Ô µÇ¾ú½À´Ï´Ù. Áø½ÉÀ¸·Î °¨»çµå¸³´Ï´Ù. Ç×»ó °Ç°­ÇϽðí, ¿Â¶óÀο¡¼­ ¶Ç´Â ¿ÀÇÁ¶óÀο¡¼­µµ ÀÚÁÖ ºËµµ·Ï ÇÏ°Ú½À´Ï´Ù. Æí¾ÈÇÑ ¹ã µÇ½Ê½Ã¿ä. °¨»çÇÕ´Ï´Ù.


[2024-3-30. ¼øõ¸¸³»½Ã°æ¼¼¹Ì³ª ÀÓ¼ºÃ¶ ±³¼ö´Ô ªÀº °­ÀÇ]

Áö³­ 2³â ¹Ý µ¿¾È Á¶¼±´ëÇб³¿¡¼­ Ä¡·áÇÑ neuroendocrine tumor ȯÀÚ 14¸íÀÇ º´¸® ½½¶óÀ̵带 ¸®ºäÇÔ. Æò±Õ 62¼¼, ³²ÀÚ 7¸í, ¿©ÀÚ 7¸í.

Synaptophysin ¿°»öÀ» ÇÏ¿´À» ¶§

³»½Ã°æ ¼Ò°ß¿¡¼­ heaped uo nodular lesionÀÌ ÀÖÀ¸¸é NET·Î Áø´ÜÇÏ°í ±×·¸Áö ¾ÊÀ¸¸é neuroendocrine hyperplasia ȤÀº dysplasia¶ó´Â ¿ë¾î¸¦ ¾²´Â °ÍÀÌ °æÇâÀÎ °Í °°´Ù.


[References]

1) ´ëÇÑ ÀÚ°¡¸é¿ª¼ºÀ§¿° ¿¬±¸È¸

2) Ç÷û Ç׺®¼¼Æ÷ Ç×ü ¾ç¼º ¼Ò°ßÀ» º¸ÀÎ ÀÚ°¡¸é¿ª¼º À§¿° ȯÀÚ 5¸í¿¡ ´ëÇÑ º¸°í Á¤Á¾Çö, À̼±¿µ µî. Ç︮ÄÚ¹ÚÅÍÇÐȸÁö 2021

3) My favorite gastric lesions by Elizabeth Anne Montgomery ÀÚ°¡¸é¿ª¼º À§¿° ¹× °ü·Ã Áúȯ (carcinoid, pyloric gland adenoma µî)¿¡ ´ëÇÑ ÇÑ º´¸®ÇÐÀÚÀÇ »ó¼¼ÇÑ ¼³¸í

3) AÇü, BÇü, ±×¸®°í ºñÀ§Ã༺ À§¿° À̼±¿µ (2023) PDF

4) Autoimmune enteropathy in children 2023/10 ±¹Á¦¼Ò¾Æ¼ÒÈ­±âÇÐȸ ¼­¿ï´ëº´¿ø Æ÷½ºÅÍ PDF

© ÀÏ¿ø³»½Ã°æ±³½Ç ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò ÀÌÁØÇà. EndoTODAY Endoscopy Learning Center. Lee Jun Haeng.